Dr. Zhu obtained his BSc and MSc degrees from Tsinghua University in China. He obtained his Ph.D. in Chemical Engineering from the University of Pittsburgh and completed his postdoctoral training at Carnegie Mellon University. In 2009 he co-founded Tianjin CanSino Biotechnology Inc., and as a senior vice president of R&D, he provides scientific and technical leadership and is responsible for company¡¯s overall R&D activities. His expertise is well recognized by Chinese biotech community. He was elected as one of the National Entrepreneurial ¡°1000-talents¡± in 2010. He was appointed as Adjunct Professor in the Faculty of Bioengineering at Tianjin University of Science and Technology.
Tao brought in multi-years of R&D experiences acquired from world biotech industry leaders. Prior founding Tianjin CanSino Biotech, he held senior scientist position in Sanofi Pasteur, a world leading vaccine company. He was responsible for the development of protein-based pneumococcal vaccines, cervical cancer vaccines, pneumococcal glycol-conjugate vaccines, recombinant TB vaccines, etc. Before joined Sanofi Pasteur, he worked for Integrate Genomics Inc. in Chicago as a research scientist, where he was involved in analyzing, sequencing, and annotating the genome of a riboflavin overexpression strain and comparative studies of
Lactobaccilli polysaccharide biosynthesis gene clusters.
Dr. Mao obtained her Ph.D. in Chemical Engineering from Chinese Academy of Sciences and then was trained as a postdoctoral research fellow at the Industrial Biotechnology Center of the University of Waterloo. She received her MBA degree from Villanova University. In 2010, Dr. Mao was elected as one of the Tianjin ¡°1000-Talents¡± and Distinguished Experts. She has also been appointed Adjunct Professor in the Faculty of Pharmacy at Tianjin University of Science & Technology.
Over the past two decades, Dr. Mao has held a variety of positions, which included Senior Research Engineer at Albright Wilson Americas Inc., Group Leader of Quality Assurance at Apotex Inc., Director of Quality Compliance at Wyeth Pharmaceuticals Inc., and Director of Quality Assurance at Endo Pharmaceuticals Inc. She has extensive expertise in diverse areas such as new drug discovery and development, production scale-up, quality assurance, regulatory affairs, etc.
Dr. Qiu earned his Ph.D. in Medicinal Chemistry from Peking University in 1987, and then received fellowship from Alexander von Humboldt foundation to pursue postdoctoral training at University Konstanz in Germany. He received his MBA from the University of Western Ontario.
Within the past 4 years, he has helped the CanSino raise US$ 20 million and directed the technology transfer of two vaccine products. Previously, he spent nine years in senior management positions with Biomira, AltaRex and Arius Research. Aside from CanSino, he also serves as MDS Capital¡¯s Director of Asian Operations and ChinaBio LLC¡¯s General Manager of China. He helped MDS Capital raise US$30 million in Taiwan and assisted the entry of three US companies into the Asian market.
Dr. Zhongqi Shao joined CanSino in 2011 as VP of R&D. He is responsible for new antigen discovery and expression, proof of concept studies on new vaccine candidates, as well as analytical science and assay development. Dr. Shao received his Ph.D. in Bacterial Physiology from Concordia University, and worked as a postdoctoral research fellow at Soils and Crops Research and Development Center of Agriculture and Agri-Food Canada. Dr. Shao was named as one of the Tianjin ¡°1000-Talents¡±.
Dr. Shao has a wealth of knowledge and experience in molecular biology, cell biology, preclinical research, etc. Prior to joining CanSino, he served as a senior scientist at Sanofi Pasteur, where he played a key role in process development, process scale-up and clinical trial material production for TB vaccines and pneumococcal vaccines. Before that, Dr. Shao had held senior research and management positions with IBEX and BioMarin Pharmaceutical Inc for 14 years. He had led the R&D activities of multiple novel medications for cancer, arthritis, and hereditary metabolic diseases. He was also involved in the preclinical study of a drug treating phenylketonuria and the technology transfer from IBEX to BioMarin.
Ms.Xu has 27 years experience in the product development, regulatory affairs and project management of vaccines, such as the Preventive and Therapeutic Hepatitis B Vaccine, MMR ( Measles, Mumps and Rubella) Vaccine, Rabies Vaccine and Varicella Vaccine etc. Prior to joining CanSino, she held a position of Deputy Director of Research and Registration in CNBG, in that role, she led the team to obtained three new drug licenses and two CTAs.
Before joined the bio-pharmaceutical industry, Ms.Xu earned her medical degree and had worked in Chengde Hospital as internist for 5 years.
Dr. Robin Harkness is CanSino¡¯s VP of International R&D relations. He obtained his Ph.D. in Microbiology from the University of Victoria, Canada and received his postdoctoral training at the Institute for Genetics and Microbiology of the University of Munich. Dr. Harkness is a senior life sciences executive with a blend of experience in the corporate, not-for-profit and consulting sectors. Over the past 20 years, he has held a variety of scientific and executive positions with Sanofi Pasteur, Canadian Cancer Alliance, and Canadian Partnership against Cancer. In 2010, he founded his own consulting firm, Harkness Biostrategies Inc., and has since been providing consulting services in biopharm and biotech areas.